Market capitalization | $762.90m |
Enterprise Value | $473.10m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.75 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-157.48m |
Free Cash Flow (TTM) Free Cash Flow | $-128.72m |
Cash position | $290.69m |
As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.
8 Analysts have issued a Pharvaris NV forecast:
8 Analysts have issued a Pharvaris NV forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.29 -0.29 |
4%
4%
|
|
EBITDA | -157 -157 |
50%
50%
|
EBIT (Operating Income) EBIT | -157 -157 |
50%
50%
|
Net Profit | -145 -145 |
33%
33%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pharvaris NV is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Hans G. C. P. Schikan and Anne Lesage on September 30, 2015 and is headquartered in Leiden, Netherlands.
Head office | Netherlands |
CEO | Berndt Modig |
Employees | 108 |
Founded | 2015 |
Website | www.pharvaris.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.